23andMe Holding Co. (NASDAQ:ME – Get Free Report) insider Kathy L. Hibbs sold 38,548 shares of 23andMe stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $0.47, for a total transaction of $18,117.56. Following the completion of the sale, the insider now owns 1,252,315 shares of the company’s stock, valued at approximately $588,588.05. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
23andMe Price Performance
Shares of ME stock traded down $0.02 during trading on Friday, reaching $0.48. The company’s stock had a trading volume of 17,180,838 shares, compared to its average volume of 7,390,713. The company has a market capitalization of $233.20 million, a price-to-earnings ratio of -0.46 and a beta of 1.27. 23andMe Holding Co. has a 1-year low of $0.35 and a 1-year high of $2.21. The stock’s 50-day moving average price is $0.54 and its 200 day moving average price is $0.73.
23andMe (NASDAQ:ME – Get Free Report) last announced its quarterly earnings data on Wednesday, February 7th. The company reported ($0.17) earnings per share (EPS) for the quarter. The company had revenue of $44.75 million during the quarter, compared to analyst estimates of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative return on equity of 52.99%.
Hedge Funds Weigh In On 23andMe
Analyst Upgrades and Downgrades
Separately, Citigroup cut their price objective on 23andMe from $0.85 to $0.47 and set a “neutral” rating on the stock in a report on Tuesday.
Get Our Latest Stock Report on ME
About 23andMe
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Read More
- Five stocks we like better than 23andMe
- What Are Dividend Achievers? An Introduction
- Comprehensive Analysis of PayPal Stock
- What is Short Interest? How to Use It
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Insider Trading – What You Need to Know
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.